The development of new methods and technologies for cell separation, sorting, selection, isolation, or enrichment (many times the aforementioned terms are used interchangeably) are becoming more imperative due in part to the wealth of research aimed at addressing issues for the analysis of liquid biopsy targets, such as rare cells, to realize the concept of "precision medicine". Precision medicine is defined as "treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a patient from others with similar clinical presentations." 1 Before full implementation of precision medicine in a hospital or clinical setting, technological discoveries must be realized to assist in the analysis of disease-associated cells enriched from complex samples.Liquid biopsy markers and the cargo that they carry have been shown to be an attractive source of information that can be used to facilitate precise decisions for disease management. These biomarkers include, but are not limited to, rare cells such as circulating tumor cells (CTCs) or cancer stem cells (CSCs), immune cells (i.e., CD8+ T-cells), bacterial and viral cells, cell-free molecules such as cell free DNA (cfDNA), and extracellular vesicles (EVs). Liquid biopsies are attractive because of the minimally invasive nature of the sampling method (i.e., collection of peripheral blood, urine, saliva) to secure relevant biomarkers. These biomarkers can enable precision medicine decisions on managing a variety of diseases, including oncology and nononcology-related diseases. 2,3 Liquid biopsies *